Protein Information

ID 557
Name plasminogen activator inhibitor
Synonyms Endothelial plasminogen activator inhibitor; PAI; PAI 1; PAI1; PAIE; PLANH 1; Plasminogen activator inhibitor 1…

Compound Information

ID 954
Name SMA
CAS sodium 2-chloroacetate

Reference

PubMed Abstract RScore(About this table)
19643931 Jung GS, Kim MK, Choe MS, Lee KM, Kim HS, Park YJ, Choi HS, Lee KU, Park KG, Lee IK: The orphan nuclear receptor SHP attenuates renal fibrosis. . J Am Soc Nephrol. 2009 Oct;20(10):2162-70. Epub 2009 Jul 30.
The accumulation of extracellular matrix proteins is a common feature of fibrotic kidney diseases. Accumulating evidence suggests that TGF-beta and plasminogen activator inhibitor type 1 (PAI-1) promote the development of renal fibrosis by stimulating the generation and inhibiting the removal of matrix proteins. The small heterodimer partner (SHP) represses PAI-1 expression in the liver by inhibiting TGF-beta signaling, but whether SHP inhibits renal fibrosis is unknown. Here, unilateral ureteral obstruction (UUO) markedly increased the expression of PAI-1, type I collagen, and fibronectin but decreased SHP gene expression. Moreover, in kidneys of SHP-/- mice, the expression of PAI-1, type I collagen, fibronectin and alpha-smooth muscle actin (alpha-SMA) were higher compared with those in kidneys of wild-type mice. In addition, loss of SHP accelerated renal fibrosis after UUO. Adenovirus-mediated overexpression of SHP in cultured rat mesangial cells and renal tubular epithelial cells inhibited TGF-beta-stimulated expression of PAI-1, type I collagen, and fibronectin. SHP inhibited TGF-beta- and Smad3-stimulated PAI-1 promoter activities as well as TGF-beta-stimulated binding of Smad3 to its consensus response element on the PAI-1 promoter. Similarly, in vivo, adenovirus-mediated overexpression of SHP in the kidney inhibited the expression of UUO-induced PAI-1, type I collagen, fibronectin, and alpha-SMA. In summary, SHP attenuates renal fibrosis in obstructive nephropathy, making its pathway a possible therapeutic target for chronic kidney disease.
1(0,0,0,1)